Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Phase II Study of Octreotide LAR as Maintenance Treatment After First-line Chemotherapy for Patients With Unresectable or Metastatic Gastro-entero-pancreatic or Esophageal Neuroendocrine Carcinomas

NCT02409849 is registered in ClinicalTrials.gov with Peking University as lead sponsor.

NCT NCT02409849
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02409849 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Phase II Study of Octreotide LAR as Maintenance Treatment After First-line Chemotherapy for Patients With Unresectable or Metastatic Gastro-entero-pancreatic or Esophageal Neuroendocrine Carcinomas
Lead sponsor
Peking University
Phase
Phase 2
Overall status
Unknown status
Start date
April 30, 2015
Completion date
June 30, 2019
Enrollment
92 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

esophageal neuroendocrine carcinoma, gastro-entero-pancreatic carcinoma